# OnCo record nct06345729 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06345729/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06345729", "NCT06345729" ;
  schema:name "A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)"@en ;
  schema:alternateName "KANDLELIT-004"@en ;
  schema:description "A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06345729/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06345729> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-05-24" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/calderasib/> ;
  onco:companies <https://onco.cc/companies/merck/> .